公开(公告)号：EP2981334A4

公开(公告)日：2016-11-23

申请号：EP14779659

申请日：2014-03-31

申请人： UNIV CALIFORNIA

发明人： LEVY JAY A

IPC分类号： A61K31/7088 ,  A61K38/17 ,  A61K45/06 ,  A61K48/00 ,  A61P31/12 ,  C07K14/47 ,  C07K14/705 ,  C12N7/00

CPC分类号： A61K38/1793 ,  A61K31/7088 ,  A61K38/17 ,  A61K38/1709 ,  A61K45/06 ,  A61K48/005 ,  C07K14/4702 ,  C07K14/70596 ,  C12N7/00 ,  C12N2710/16111 ,  C12N2710/16163 ,  C12N2710/16511 ,  C12N2710/16563 ,  C12N2720/12311 ,  C12N2720/12363 ,  C12N2740/16011 ,  C12N2740/16063 ,  C12N2760/10011 ,  C12N2760/14111 ,  C12N2760/18063 ,  C12N2760/18211 ,  C12N2770/24111 ,  C12N2770/24163 ,  C12N2770/32311 ,  C12N2770/32663 ,  C12N2770/32763 ,  A61K2300/00

摘要： The present disclosure provides methods of inhibiting viral activity in a cell, the methods generally involving contacting the cell with a soluble CD137 polypeptide or a FAM3C polypeptide. The present disclosure provides methods for treating a virus infection in an individual, the methods generally involving administering to the individual an effective amount of a soluble CD137 polypeptide or a FAM3C polypeptide.

公开(公告)号：EP2981334A1

公开(公告)日：2016-02-10

申请号：EP14779659.3

申请日：2014-03-31

申请人： The Regents of the University of California

发明人： LEVY, Jay A.

IPC分类号： A61P31/12

CPC分类号： A61K38/1793 ,  A61K31/7088 ,  A61K38/17 ,  A61K38/1709 ,  A61K45/06 ,  A61K48/005 ,  C07K14/4702 ,  C07K14/70596 ,  C12N7/00 ,  C12N2710/16111 ,  C12N2710/16163 ,  C12N2710/16511 ,  C12N2710/16563 ,  C12N2720/12311 ,  C12N2720/12363 ,  C12N2740/16011 ,  C12N2740/16063 ,  C12N2760/10011 ,  C12N2760/14111 ,  C12N2760/18063 ,  C12N2760/18211 ,  C12N2770/24111 ,  C12N2770/24163 ,  C12N2770/32311 ,  C12N2770/32663 ,  C12N2770/32763 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/389 ,  Y02A50/465 ,  A61K2300/00

摘要： The present disclosure provides methods of inhibiting viral activity in a cell, the methods generally involving contacting the cell with a soluble CD137 polypeptide or a FAM3C polypeptide. The present disclosure provides methods for treating a virus infection in an individual, the methods generally involving administering to the individual an effective amount of a soluble CD137 polypeptide or a FAM3C polypeptide.